BRPI0620983B8 - uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico - Google Patents
uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópicoInfo
- Publication number
- BRPI0620983B8 BRPI0620983B8 BRPI0620983A BRPI0620983A BRPI0620983B8 BR PI0620983 B8 BRPI0620983 B8 BR PI0620983B8 BR PI0620983 A BRPI0620983 A BR PI0620983A BR PI0620983 A BRPI0620983 A BR PI0620983A BR PI0620983 B8 BRPI0620983 B8 BR PI0620983B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- manufacture
- triazine derivatives
- drug
- derivatives
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003918 triazines Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 230000002491 angiogenic effect Effects 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600347A FR2896161B1 (fr) | 2006-01-13 | 2006-01-13 | Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. |
| FR0600347 | 2006-01-13 | ||
| PCT/EP2006/012183 WO2007079915A2 (en) | 2006-01-13 | 2006-12-18 | Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0620983A2 BRPI0620983A2 (pt) | 2011-11-29 |
| BRPI0620983B1 BRPI0620983B1 (pt) | 2019-09-17 |
| BRPI0620983B8 true BRPI0620983B8 (pt) | 2021-05-25 |
Family
ID=36658622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0620983A BRPI0620983B8 (pt) | 2006-01-13 | 2006-12-18 | uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8217040B2 (enExample) |
| EP (1) | EP1971329B1 (enExample) |
| JP (1) | JP2009523140A (enExample) |
| KR (1) | KR101482686B1 (enExample) |
| CN (1) | CN101355931A (enExample) |
| AR (1) | AR059034A1 (enExample) |
| AU (1) | AU2006334732B2 (enExample) |
| BR (1) | BRPI0620983B8 (enExample) |
| CA (1) | CA2636838C (enExample) |
| CY (1) | CY1119872T1 (enExample) |
| DK (1) | DK1971329T3 (enExample) |
| EA (1) | EA016127B1 (enExample) |
| ES (1) | ES2647912T3 (enExample) |
| FR (1) | FR2896161B1 (enExample) |
| HU (1) | HUE037217T2 (enExample) |
| IL (1) | IL192595A (enExample) |
| LT (1) | LT1971329T (enExample) |
| PL (1) | PL1971329T3 (enExample) |
| PT (1) | PT1971329T (enExample) |
| SI (1) | SI1971329T1 (enExample) |
| WO (1) | WO2007079915A2 (enExample) |
| ZA (1) | ZA200806946B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2948027A1 (fr) * | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| JP2020536121A (ja) | 2017-10-02 | 2020-12-10 | ポクセルＰｏｘｅｌ | 駆出率が保持された心不全を治療する方法 |
| CA3102412A1 (en) | 2018-06-06 | 2019-12-12 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| WO2019238647A1 (en) | 2018-06-14 | 2019-12-19 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| EP4014962A1 (de) * | 2020-12-16 | 2022-06-22 | Novigo GmbH & Co. KG | Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung |
| FR3149774B1 (fr) * | 2024-01-11 | 2025-06-20 | Fabre Pierre Dermo Cosmetique | 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150362A (en) * | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
| DK1037886T3 (da) * | 1997-12-12 | 2003-08-25 | Abbott Lab | Triazin angiogeneseinhibitorer |
| FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| AU2003289375A1 (en) * | 2002-12-17 | 2004-07-09 | Hamari Chemicals, Ltd | Novel 2,4-diamino-1,3,5-triazine derivative |
| FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
-
2006
- 2006-01-13 FR FR0600347A patent/FR2896161B1/fr not_active Expired - Fee Related
- 2006-12-18 CA CA2636838A patent/CA2636838C/en not_active Expired - Fee Related
- 2006-12-18 US US12/160,515 patent/US8217040B2/en not_active Expired - Fee Related
- 2006-12-18 PT PT68297043T patent/PT1971329T/pt unknown
- 2006-12-18 LT LTEP06829704.3T patent/LT1971329T/lt unknown
- 2006-12-18 WO PCT/EP2006/012183 patent/WO2007079915A2/en not_active Ceased
- 2006-12-18 JP JP2008549781A patent/JP2009523140A/ja active Pending
- 2006-12-18 ES ES06829704.3T patent/ES2647912T3/es active Active
- 2006-12-18 BR BRPI0620983A patent/BRPI0620983B8/pt not_active IP Right Cessation
- 2006-12-18 CN CNA200680050807XA patent/CN101355931A/zh active Pending
- 2006-12-18 AU AU2006334732A patent/AU2006334732B2/en not_active Ceased
- 2006-12-18 SI SI200632225T patent/SI1971329T1/en unknown
- 2006-12-18 PL PL06829704T patent/PL1971329T3/pl unknown
- 2006-12-18 EP EP06829704.3A patent/EP1971329B1/en active Active
- 2006-12-18 KR KR1020087019389A patent/KR101482686B1/ko not_active Expired - Fee Related
- 2006-12-18 DK DK06829704.3T patent/DK1971329T3/en active
- 2006-12-18 EA EA200801678A patent/EA016127B1/ru not_active IP Right Cessation
- 2006-12-18 HU HUE06829704A patent/HUE037217T2/hu unknown
-
2007
- 2007-01-12 AR ARP070100140A patent/AR059034A1/es unknown
-
2008
- 2008-07-02 IL IL192595A patent/IL192595A/en active IP Right Grant
- 2008-08-12 ZA ZA200806946A patent/ZA200806946B/xx unknown
-
2017
- 2017-11-27 CY CY20171101240T patent/CY1119872T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1971329T1 (en) | 2018-03-30 |
| WO2007079915A2 (en) | 2007-07-19 |
| JP2009523140A (ja) | 2009-06-18 |
| ZA200806946B (en) | 2009-11-25 |
| BRPI0620983A2 (pt) | 2011-11-29 |
| AU2006334732B2 (en) | 2012-05-17 |
| CN101355931A (zh) | 2009-01-28 |
| EP1971329A2 (en) | 2008-09-24 |
| CA2636838A1 (en) | 2007-07-19 |
| PT1971329T (pt) | 2017-11-24 |
| ES2647912T3 (es) | 2017-12-27 |
| PL1971329T3 (pl) | 2018-03-30 |
| EP1971329B1 (en) | 2017-10-11 |
| HUE037217T2 (hu) | 2018-08-28 |
| AR059034A1 (es) | 2008-03-12 |
| EA200801678A1 (ru) | 2008-12-30 |
| EA016127B1 (ru) | 2012-02-28 |
| DK1971329T3 (en) | 2017-12-04 |
| KR101482686B1 (ko) | 2015-01-14 |
| BRPI0620983B1 (pt) | 2019-09-17 |
| FR2896161B1 (fr) | 2008-04-04 |
| LT1971329T (lt) | 2018-01-25 |
| WO2007079915A3 (en) | 2007-08-30 |
| IL192595A0 (en) | 2009-02-11 |
| IL192595A (en) | 2013-04-30 |
| US20100168115A1 (en) | 2010-07-01 |
| CA2636838C (en) | 2015-05-05 |
| FR2896161A1 (fr) | 2007-07-20 |
| US8217040B2 (en) | 2012-07-10 |
| AU2006334732A1 (en) | 2007-07-19 |
| KR20080088629A (ko) | 2008-10-02 |
| CY1119872T1 (el) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| GT200900095A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas. | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0714553B8 (pt) | derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| BRPI0714803B8 (pt) | compostos peptidomiméticos de smac, seus usos, e composição farmacêutica | |
| BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
| BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
| BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BRPI0915064B8 (pt) | derivados de quinoxalinadiona, seus usos, e medicamentos | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| BR112012016330B8 (pt) | ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos | |
| BRPI0908124A2 (pt) | Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
| SV2010003674A (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: POXEL S.A.S (FR) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |